Five challenges limiting widespread adoption of microbiome-based diagnostics
This article was originally published in Technology Networks. As several microbiome-based therapeutics, which manipulate and restore the body’s gut bacteria,...
Robert Broadnax has more than 17 years of pharma/biotech commercialization, sales, and advanced analytics experience ranging from early pipeline to in-line brands with expertise in specialty disease areas, including Oncology, Immunology and Virology.
Mr. Broadnax has developed and executed global and regional go to market strategies, launched new products in competitive marketplaces, and helped numerous clients identify, prioritize and execute market opportunities to achieve financial and operational objectives. His expertise includes commercialization strategy, analytics and customer insights.
Prior to joining CRA, Mr. Broadnax spent most of his career in leadership roles on the client side of the pharma/biotech industry at Bristol-Myers Squibb, UCB Inc. and Roche Pharmaceuticals. He has also has been a Partner at C1 Consulting and General Manager of TRM Oncology.